
24 June 2026
GenIP Plc
("GenIP" or the "Company")
Senior Innovation Roundtable Hosted with Knowledge Exchange UK
GenIP hosted a closed-door senior roundtable earlier this week in partnership with Knowledge Exchange UK (KEUK), bringing together more than twenty of the UK's most senior figures in research commercialisation, technology transfer, and science policy.
The room carried significant weight. Attendees included senior decision-makers from Russell Group and research-intensive universities, the UK Government, leading national research agencies, and international bodies including the Association of Commonwealth Universities. The session was chaired by Lord Willetts, former Minister for Universities and Science and Non-Executive Director of GenIP, with the discussion led by the Chief Executive of KEUK.
Attendees included existing GenIP clients and prospects.
Discussion focused on the role of AI in reshaping technology transfer, reinforcing GenIP's market positioning, with consensus that intelligent, expert-led use of AI tools is the direction the sector is moving, not automation for its own sake.
The Board views events of this calibre as central to GenIP's commercial development strategy and will provide further updates on outcomes in due course.
For further information regarding GenIP, please visit www.genip.ai, or contact:
|
GenIP Plc Melissa Cruz, CEO |
|
Via Redchurch Communications |
|
|
|
|
|
AlbR Capital Limited (Joint Broker) Colin Rowbury Jon Belliss
|
|
Tel: +44 (0)20 7399 9427
|
|
CMC Markets (Joint Broker) |
|
Tel: + 44 (0) 203 003 8632 |
|
Douglas Crippen |
|
|
|
|
|
|
|
Redchurch Communications (Financial PR) John Casey
|
|
|
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Notes to Editors
About GenIP
GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
|
Service |
Description |
Value Proposition |
|
Invention Intelligence Product Suite |
AI-powered market intelligence reports assessing the commercial potential of emerging technologies |
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
|
IP Commercialization Services
|
End-to-end engagement to help research organisations commercialise innovations
|
Provides cost-effective, broad support to achieve our clients' strategic objectives
|
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
● Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
● Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
● Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
Forward looking statements
Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.
Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".
For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.
-ENDS-